---
title: "United Therapeutics Says Pulmonary Arterial Hypertension Treatment Meets Primary Endpoint in Late-Stage Trial"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286741658.md"
description: "United Therapeutics' phase 3 trial of ralinepag for pulmonary arterial hypertension met its primary endpoint, reducing clinical worsening events by 55% compared to placebo. The company plans to file a new drug application with the FDA in H2 2026."
datetime: "2026-05-18T08:43:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286741658.md)
  - [en](https://longbridge.com/en/news/286741658.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286741658.md)
---

# United Therapeutics Says Pulmonary Arterial Hypertension Treatment Meets Primary Endpoint in Late-Stage Trial

04:43 AM EDT, 05/18/2026 (MT Newswires) -- United Therapeutics' ( UTHR ) phase 3 trial of ralinepag in patients with pulmonary arterial hypertension met its primary endpoint, the company said Sunday.

The treatment cut the risk of clinical worsening events by 55%, compared with placebo, with secondary endpoints also demonstrating favorable outcomes, the company said.

United Therapeutics ( UTHR ) plans to file a new drug application with the US Food and Drug Administration for ralinepag in H2 2026.

Pulmonary arterial hypertension is a life-threatening disease that impacts the blood vessels in the lungs and is characterized by increased pressure in the pulmonary arteries.

MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.

### Related Stocks

- [UTHR.US](https://longbridge.com/en/quote/UTHR.US.md)

## Related News & Research

- [United Therapeutics Corporation Announces ADVANCE OUTCOMES Study of Ralinepag Presented at ATS 2026 | UTHR Stock News](https://longbridge.com/en/news/286679932.md)
- [Ameritas Advisory Services LLC Boosts Stake in United Therapeutics Corporation $UTHR](https://longbridge.com/en/news/286373098.md)
- [TD Cowen Reaffirms Their Buy Rating on United Therapeutics (UTHR)](https://longbridge.com/en/news/286711472.md)
- [United Therapeutics (NASDAQ:UTHR) CFO James Edgemond Sells 10,000 Shares](https://longbridge.com/en/news/286643771.md)
- [Varda Space Industries and United Therapeutics Collaborate to Advance Microgravity-Enabled Treatments for Rare Pulmonary Disease | UTHR Stock News](https://longbridge.com/en/news/286236984.md)